Hall et al. assessed patients with synucleinopathies (PD, MSA, DLB, and PDD), tauopathies (PSP, CBD, and AD) and healthy controls using a panel of compounds: alpha-synuclein, total tau protein, hyperphosphorylated tau, Aβ42, and NFL. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.